Market Place
Sourcing Support
All News #Library
Rare Diseases
Pierre Fabre Pharma Responds to Fda`s CRL for Tabelecleucel
12 Jan 2026 //
PR NEWSWIRE
Pierre Fabre Announces Phase 3 Tabelecleucel Data in EBV+ PTLD
08 Dec 2025 //
PR NEWSWIRE
Pierre Fabre Pharma Acquires Tabelecleucel BLA For EBV+ PTLD
03 Nov 2025 //
PR NEWSWIRE
FDA Accepts Pierre Fabre’s Tabelecleucel for Priority Review
24 Jul 2025 //
PR NEWSWIRE
FDA declines to approve Atara Biotherapeutics` cancer therapy
17 Jan 2025 //
PRESS RELEASE
Pierre Fabre Pursues Innovative Therapies For Rare Pediatric Diseases
29 Feb 2024 //
PRESS RELEASE
Pierre Fabre committed to combating rare pediatric diseases via therapies
23 Feb 2024 //
PR NEWSWIRE
Pierre Fabre pursues commitment against rare diseases in the pediatric fields.
06 Feb 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.